United Therapeutics Corporation (UTHR) Receives $128.60 Average Price Target from Analysts

United Therapeutics Corporation (NASDAQ:UTHR) has been assigned an average recommendation of “Hold” from the sixteen research firms that are presently covering the stock, Marketbeat reports. Five investment analysts have rated the stock with a sell rating, seven have given a hold rating and three have issued a buy rating on the company. The average twelve-month target price among analysts that have covered the stock in the last year is $128.60.

A number of equities analysts have commented on the stock. Cowen and Company reaffirmed a “hold” rating and set a $129.00 target price on shares of United Therapeutics Corporation in a research note on Friday, October 27th. HC Wainwright reaffirmed a “hold” rating and set a $95.00 target price on shares of United Therapeutics Corporation in a research note on Thursday, October 26th. Zacks Investment Research raised shares of United Therapeutics Corporation from a “strong sell” rating to a “hold” rating in a research note on Monday, October 9th. TheStreet downgraded shares of United Therapeutics Corporation from a “b-” rating to a “c” rating in a research note on Friday, September 29th. Finally, ValuEngine raised shares of United Therapeutics Corporation from a “hold” rating to a “buy” rating in a research note on Monday, October 2nd.

In related news, CEO Martine A. Rothblatt sold 1,238 shares of United Therapeutics Corporation stock in a transaction that occurred on Thursday, August 24th. The shares were sold at an average price of $130.65, for a total value of $161,744.70. Following the completion of the transaction, the chief executive officer now owns 2,307 shares in the company, valued at $301,409.55. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Martine A. Rothblatt sold 1,235 shares of United Therapeutics Corporation stock in a transaction that occurred on Thursday, August 31st. The shares were sold at an average price of $130.49, for a total transaction of $161,155.15. Following the completion of the transaction, the chief executive officer now owns 2,304 shares of the company’s stock, valued at approximately $300,648.96. The disclosure for this sale can be found here. Insiders sold a total of 16,793 shares of company stock worth $2,081,621 over the last three months. Insiders own 7.80% of the company’s stock.

Several hedge funds have recently made changes to their positions in the stock. Wells Fargo & Company MN grew its holdings in United Therapeutics Corporation by 144.0% during the 2nd quarter. Wells Fargo & Company MN now owns 730,634 shares of the biotechnology company’s stock worth $94,785,000 after acquiring an additional 431,210 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in United Therapeutics Corporation by 308.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 500,499 shares of the biotechnology company’s stock worth $64,930,000 after acquiring an additional 378,002 shares in the last quarter. Renaissance Technologies LLC grew its holdings in United Therapeutics Corporation by 65.5% during the 2nd quarter. Renaissance Technologies LLC now owns 837,600 shares of the biotechnology company’s stock worth $108,662,000 after acquiring an additional 331,400 shares in the last quarter. Schroder Investment Management Group grew its holdings in United Therapeutics Corporation by 42.8% during the 2nd quarter. Schroder Investment Management Group now owns 1,091,675 shares of the biotechnology company’s stock worth $143,359,000 after acquiring an additional 327,360 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in United Therapeutics Corporation by 58.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 726,760 shares of the biotechnology company’s stock worth $94,286,000 after acquiring an additional 266,790 shares in the last quarter.

United Therapeutics Corporation (NASDAQ:UTHR) traded down $0.23 on Friday, reaching $121.00. 190,618 shares of the company were exchanged, compared to its average volume of 569,661. The firm has a market capitalization of $5,220.00, a price-to-earnings ratio of 10.89 and a beta of 1.38. United Therapeutics Corporation has a 52-week low of $112.01 and a 52-week high of $169.89.

United Therapeutics Corporation (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, October 25th. The biotechnology company reported $6.27 earnings per share for the quarter, topping analysts’ consensus estimates of $4.01 by $2.26. The firm had revenue of $445.50 million for the quarter, compared to analyst estimates of $426.43 million. United Therapeutics Corporation had a net margin of 30.50% and a return on equity of 26.24%. United Therapeutics Corporation’s quarterly revenue was up 9.1% on a year-over-year basis. During the same period in the previous year, the business posted $4.23 earnings per share. analysts forecast that United Therapeutics Corporation will post 11.92 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “United Therapeutics Corporation (UTHR) Receives $128.60 Average Price Target from Analysts” was posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this article on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The legal version of this article can be accessed at https://ledgergazette.com/2017/11/19/united-therapeutics-corporation-uthr-receives-128-60-average-price-target-from-analysts.html.

United Therapeutics Corporation Company Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Analyst Recommendations for United Therapeutics Corporation (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply